Physician
Endocrinology
Dr. Nelson B. Watts, MD
|
|
Give Review
Nelson Watts is an expert in the field of Endocrinology. He went to University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is a top medical university. University of North Carolina at Chapel Hill School of Medicine is ranked 22/2 in Research/PrimaryCare. He received 2 awards: "America's Top Doctors" and "CMS Meaningful Use Stage 1 Certification". Nelson Watts is also a published doctor. He has 82 paper published. The most recent paper is: Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. He is registered with Medicare.
Publications
- Urinary Tract Stones and Osteoporosis: Findings From the Women's Health Initiative.
- Erratum to: Taxonomy of rare genetic metabolic bone Disorders.
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
- Comparison of Fracture Risk Prediction by the US Preventive Services Task Force Strategy and Two Alternative Strategies in Women 50-64 Years Old in the Women's Health ...
- Associations of Menopausal Vasomotor Symptoms with Fracture Incidence.
- International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study.
- Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
- Advances in target-specific therapy for Osteoporosis.
- The clinical diagnosis of Osteoporosis: a position statement from the National Bone Health Alliance Working Group.
- Empirically Based Composite Fracture Prediction Model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).
- Osteoporosis Screening in Postmenopausal Women 50-64 Years-Old: Comparison of U.S. Preventive Services Task Force Strategy and Two Traditional Strategies in the Women'...
- Chronic Kidney Disease Mineral and Bone Disorders (CKD-MBD) What the Endocrinologist Needs to Know.
- Denosumab in Osteoporosis.
- Secondary Osteoporosis: differential diagnosis and workup.
- A Clinician Performance Initiative to Improve Quality of Care for Patients with Osteoporosis.
- 2013 ISCD Position Development Conference: Task Force on Normative Databases.
- Use of drug holidays in women taking bisphosphonates.
- Bisphosphonate drug holiday: who, when and how long.
- Diagnosis and treatment of Osteoporosis in older adults.
- Skeletal health in long-duration astronauts: Nature, assessment and management recommendations from the NASA bone summit.
- Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of Osteoporosis in women.
- Fracture risk in glucocorticoid-induced Osteoporosis.
- Predicting fractures in an international cohort using risk factor algorithms, without bone mineral density.
- Regional differences in treatment for Osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).
- The Fracture Risk Assessment Tool (FRAX(®)): Applications in Clinical Practice.
- A backbone for FRAX?
- Bisphosphonates for postmenopausal Osteoporosis.
- Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence.
- Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.
- Osteoporosis update from the 2010 santa fe bone symposium.
- Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008.
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal Osteoporosis: executive su...
- Adverse events and intravenous versus oral bisphosphonate use in patients with Osteoporosis and cancer in the U.S.
- Dynamic bone quality: a noninvasive measure of bone's biomechanical property in Osteoporosis.
- Long-term use of bisphosphonates in Osteoporosis.
- Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo.
- Clinical value of monitoring BMD in patients treated with bisphosphonates for Osteoporosis.
- FRAX facts.
- Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment.
- Management of Osteoporosis among home health and long-term care patients with a prior fracture.
- New guidelines for the prevention and treatment of Osteoporosis.
- Early responsiveness of women with Osteoporosis to teriparatide after therapy with alendronate or risedronate.
- National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FR...
- Osteonecrosis of the jaw.
- Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for Osteoporosis.
- Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
- Effect of precision error on T-scores and the diagnostic classification of bone status.
- Intraoperative PTH: effect of sample timing and Vitamin D status.
- Bone quantity and quality of youths working on a farm-a pilot study.
- Bisphosphonates and osteonecrosis of the jaw.
- Type 2 Diabetes, thiazolidinediones: bad to the bone?
- Comparison of serum calcium change following Thyroid and nonThyroid neck surgery.
- Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver Disease.
- What is Osteopenia, and what should be done about it?
- Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to chang...
- Review of treatment modalities for postmenopausal Osteoporosis.
- Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study.
- Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
- Guide to bone health and Disease in cystic fibrosis.
- Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen.
- Diagnosis and evaluation of patients with Osteoporosis.
- A comparison of the effects of raloxifene and conjugated equine estrogen on bone and Lipids in healthy postmenopausal women.
- Is it ethical to use placebos in Osteoporosis clinical trials?
- Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
- The effect of octreotide on paraThyroid carcinoma.
- Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
- Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate t...
- The American College of Endocrinology and Endocrine University.
- Position Development Conference.
- Bisphosphonate treatment of Osteoporosis.
- Efficacy of teriparatide and alendronate on nonvertebral fractures.
- Is percutaneous vertebral augmentation (vertebroplasty) effective treatment for painful vertebral fractures?
- Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
- Lessons from the Women's Health Initiative.
- Diagnosis and management of vertebral fractures in elderly adults.
- Bone quality: getting closer to a definition.
- Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline.
- Clinical challenges in Osteoporosis. Case 1: screening for Osteoporosis in early menopause.
- Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.
- Position statements of the International Society for Clinical Densitometry: methodology.
Schools
University of North Carolina At Chapel Hill
Eugene Talmadge Meml Hospital
Charlotte Meml Hospital
North Carolina Memorial Hospital
Conditions Treated
- Abnormal Thyroid
- Adrenal Incidentaloma
- Adrenal Insufficiency
- Calcium Metabolism Disorders
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
Education
-
Carolinas Medical Center -
Medical College of Georgia -
University of North Carolina at Chapel Hill School of Medicine
Drug Facts
| NPI NUMBER | 1740238229 | |
| NPPES Provider LastName | WATTS | |
| NPPES Provider FirstName | NELSON | |
| NPPES Provider ZIPCode | 452366703 | |
| NPPES Provider State | OH | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 716.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740238229 |
| Last Name Of The Provider | WATTS |
| First Name Of The Provider | NELSON |
| View All |
Similar Doctors
|
|
Dr. Dummi P. Yathiraj, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth Kreines, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold T. Pretorius, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naila M. Goldenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah D. Corathers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nadia Yaqub, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mercedes Falciglia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Dalessio, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Hurd, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jenny Tong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Padma Mangu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silvana Obici, MD
This Doctor is OpenDoctor Recommended.
|